Abstract
Retrospective Analysis of Neutralizing Antibody Cocktail (Casirivimab and Imdevimab): A Game Changer in Treating Mild COVID-19 Patients
Department of General Medicine, Dr. D.Y. Patil Medical College, Hospital & Research Centre, Dr. D.Y. Patil Vidyapeeth, 1Department of Public Health Dentistry, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pimpri, Pune, Maharashtra 411018, 2Senior Resident, Krishna Institute of Medical Sciences, Secunderabad, Telangana 500003, India, 3Department of Family and Community Medicine, College of Medicine, Majmaah University, Al Majmaah 11952, 4Ministry of Health, Riyadh 12478, 5Department of Medical Laboratories, College of Applied Medical Sciences, 6Department of Pharmacy Practice, College of Pharmacy, Shaqra University, Shaqra 11961, 7Department of Applied Medical Science, Buraydah Private Colleges, Buraydah 51418, 8Department of Medicine, 9Department of Neurology, College of Medicine, Majmaah University, Al Majmaah 11952, 10Department of Medicine, Faculty of Medicine, 11Department of Surgery, Faculty of Medicine, Umm Al-Qura University, Makkah 24382, 12Department of Family and Community Medicine, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, 13Department of Medicine, Ministry of National Guard-Health Affairs, Ar Rimayah, Riyadh 11426, 14King Abdullah International Medical Research Center, Ar Rimayah, Riyadh 11481, 15King Saud bin Abdulaziz University for Health Sciences, Riyadh, Ar Rimayah, Riyadh 14611, Saudi Arabia
Correspondence Address:
Sharif Alhajlah, Department of Medical Laboratories, College of Applied Medical Sciences, Shaqra University, Shaqra 11961, Saudi Arabia, E-mail: alhjlah@su.edu.sa
Our retrospective study aimed to evaluate the effectiveness of monoclonal antibodies (casirivimab and imdevimab) on mild cases of coronavirus disease 2019 patients admitted to the tertiary care center. A total of 161 patients were evaluated of which the test group consisted of 79 and the control group of 82. In the test group the patients had been administered with diluted 250 ml of 0.9 % sodium chloride along with co-formulated casirivimab (600 mg) and imdevimab (600 mg) solution intravenously and in the control group the patients were administered standard coronavirus disease 2019 treatment protocol. The monitoring of patients in both groups was done at least 1 h after drug infusion in the designated room. Post-treatment designed interviews were taken to evaluate the effectiveness of treatment. This retrospective analysis discovered a significant association of symptoms with the group at 48 h for injected and non-injected patients and 1 mo from the chi-square test after injecting monoclonal antibodies. There is no significant association of symptoms with the groups at 3 mo. A significant difference in the symptom distribution through different time points in the injected group and not injected group was observed. From the pairwise McNemar’s test, a significant difference in the symptoms between each time in 48 h, the difference was p=0.0075 and after 1 mo, p<0.001 points in both groups. The combination of casirivimab and imdevimab could be considered a treatment of choice for vaccinated, non-vaccinated and mild to highrisk coronavirus disease 2019 patients.
